18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer
暂无分享,去创建一个
Orazio Schillaci | Giovanni Simonetti | C. Cicciò | F. Calabria | R. Danieli | O. Schillaci | G. Simonetti | A. Orlacchio | M. Carlani | Antonio Orlacchio | Roberta Danieli | Marco Carlani | Ferdinando Calabria | Mario Tavolozza | Carmelo Cicciò | Cristiana R Caracciolo | C. Caracciolo | M. Tavolozza
[1] T. DeGrado,et al. Cancer imaging with fluorine-18-labeled choline derivatives. , 2007, Seminars in nuclear medicine.
[2] Tomio Inoue,et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging , 2001, European Journal of Nuclear Medicine.
[3] J. Mercer. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[4] Akira Matsumura,et al. New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma , 2008, European Radiology.
[5] N. Blumstein,et al. PET und PET/CT in der Rezidivdiagnostik des Prostatakarzinoms , 2006, Der Urologe.
[6] Osama Mawlawi,et al. PET/CT imaging artifacts. , 2005, Journal of nuclear medicine technology.
[7] M. Picchio,et al. PET-CT for treatment planning in prostate cancer. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[8] A. Pupi,et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer , 2008, La radiologia medica.
[9] M. Schwaiger,et al. The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[10] M. Soler,et al. PET/TAC con 11C-colina y 18F-FDG en pacientes con elevación de PSA tras tratamiento radical de un cáncer de próstata , 2009 .
[11] H. Groen,et al. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer]. , 2009, Revista espanola de medicina nuclear.
[13] L. Kostakoglu,et al. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.
[14] J. Pruim,et al. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? , 2001, European Journal of Nuclear Medicine.
[15] B. Weber,et al. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[16] G. Cook,et al. Pitfalls in PET/CT interpretation. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[17] G. Glatting,et al. [PET and PET/CT in relapsing prostate carcinoma]. , 2006, Der Urologe. Ausg. A.
[18] I. Fogelman,et al. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. , 2006, Seminars in nuclear medicine.
[19] Jing-han Chen,et al. The role of 11C‐choline positron emission tomographycomputed tomography and videomediastinoscopy in the evaluation of diseases of middle mediastinum , 2006, Chinese medical journal.